Connexin-based signaling in acute myelogenous leukemia (AML)
نویسندگان
چکیده
منابع مشابه
How mRNA is misspliced in acute myelogenous leukemia (AML)?
Approximately one-third of expressed genes are misspliced in AML, opening the possibility that additional factors than splicing factor mutations might cause RNA missplicing in these diseases. AML cells harbor a constellation of epigenetic modifications and regularly express large amounts of WT1 transcripts. Histone acetylation/methylation and DNA CpG methylation favor either exon skipping or in...
متن کاملFamilial Acute Myelogenous Leukemia: Report of Three Cases
Acute myelogenous leukemia (AML) is a hematological malignancy, which accounts for about 15-25% of childhood's leukemia. Genetic factor is one of the most important predisposing elements in childhood acute leukemia, especially AML. In this case report, a rare presentation of familial AML is presented in three monozygotic triplets. Two were 10 months old, and the other one was 16 months old at p...
متن کاملEffective Dendritic Cell-based Immunotherapeutic Vaccines for Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) is a type of poor prognosis hematological malignancies characterized by heterogeneous clonal expansion of myeloid progenitors. Leukemic stem cells are thought to form the majority of a cell population in minimal residual diseases (MRDs) which are resistant to current chemotherapeutic regimens and mediate disease relapse. Current therapeutic vaccine strategies have d...
متن کاملAcute Myelogenous Leukemia
Acute myeloid leukemia is not a single disease but a group of neoplastic disorders. The malignant cells gradually replace, and inhibit the growth and maturation of, normal erythroid, myeloid, and megakaryocytic precursors. Included among the names for this condition are acute myelogenous leukemia, acute myelocytic leukemia, acute myeloid leukemia, acute myeloblastic leukemia, acute granulocytic...
متن کاملAcute Myelogenous Leukemia
Documented central nervous system (CNS) involvement in acute myelogenous leukemia (AML), unlike acute lymphocytic leukemia, is relatively uncommon [1 , 2] . CNS involvement in AML is reported to occur in 6%-17% of cases [1-4]. It is expected that improvements in therapy with increased frequency of remission and prolonged survival will lead to further increases in clinical CNS involvement in AML...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biochimica et Biophysica Acta (BBA) - Biomembranes
سال: 2010
ISSN: 0005-2736
DOI: 10.1016/j.bbamem.2009.10.014